PMID-33473109 – MOTS-c Exercise-Induced Regulator of Age-Dependent Physical Decline

PMID-33473109 – MOTS-c: Exercise-Induced Regulator of Age-Dependent Physical Decline

Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis," Nature Communications, 2021;12(1):470. doi:10.1038/s41467-020-20790-0

Quick Reference

Property Value
PMID 33473109
DOI 10.1038/s41467-020-20790-0
Year 2021
Journal Nature Communications
Study Type Animal in vivo + Human observational
Evidence Level III
Sample Young, middle-aged, and old mice + human exercise cohort
Peptide(s) Studied MOTS-C

Key Findings

  • MOTS-c treatment significantly enhanced physical performance in young, middle-aged, AND old mice
  • Late-life MOTS-c treatment (initiated at 23.5 months) reversed age-dependent physical decline
  • Exercise induces endogenous MOTS-c expression in skeletal muscle and circulation in both mice and humans
  • MOTS-c improved muscle homeostasis and metabolic function in aged animals
  • Human component: exercise upregulates MOTS-c in skeletal muscle (observational cohort)

Study Design

Multi-component: (1) MOTS-c IP injection in mice at different life stages with physical performance testing; (2) Muscle transcriptomics and metabolomics; (3) Human exercise cohort measuring MOTS-c levels in skeletal muscle biopsies pre/post exercise.

Limitations

  • Mouse intervention data; human component is observational only (no MOTS-c administration in humans)
  • Late-life intervention window not tested across full lifespan
  • Dosing may not translate directly to human protocols

Clinical Relevance

Landmark study from the Lee lab (MOTS-c discoverer). The combination of mouse intervention and human observational data provides the strongest translational evidence for MOTS-c as an exercise mimetic. The late-life efficacy finding is particularly relevant for anti-aging and sarcopenia applications. Published in Nature Communications (high-impact). Evidence Level III due to the human observational component.

Related

#research #animal-in-vivo #evidence-level-III